Enhancing Self Care Among Oral Cancer Survivors: The Empowered Survival Trial

Sponsor
Rutgers, The State University of New Jersey (Other)
Overall Status
Recruiting
CT.gov ID
NCT04713449
Collaborator
National Cancer Institute (NCI) (NIH), The Cancer Registry of Greater California (Other), The New Jersey State Cancer Registry (Other)
600
1
2
49.3
12.2

Study Details

Study Description

Brief Summary

Project's goal is evaluate an online tool the research team created called Empowered Survivor (ES) against a free online self-management intervention developed for cancer survivors by the National Cancer Institute and the American Cancer Society called Springboard Beyond Cancer.

Condition or Disease Intervention/Treatment Phase
  • Other: Empowered Survivor Online
  • Other: Springboard Beyond Cancer
  • Other: Survey Administration
N/A

Detailed Description

600 patients who have completed treatment between one and three years ago and are currently cancer-free will be recruited via the New Jersey State Cancer Registry or the Cancer Registry of Greater California and randomly assigned to ES or Springboard Beyond Cancer. Participants will complete measures at baseline, 2, and 6-months post-baseline. The investigators will also complete a process evaluation of Empowered Survivor.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
600 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Other
Official Title:
Enhancing Self Care Among Oral Cancer Survivors: The Empowered Survivor Trial
Actual Study Start Date :
Jan 19, 2021
Anticipated Primary Completion Date :
Mar 1, 2025
Anticipated Study Completion Date :
Mar 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: Empowered Survivor online

The online intervention, called Empowered Survivor (ES) is a self-management intervention for patients with head and neck cancer. The intervention contains the following modules: Introduction; Difficulty Swallowing and Muscle Strength; Oral Care; Long-term Follow-Up Care/Oral exams; Calm and Connect; and Maintaining.

Other: Empowered Survivor Online
Informational online intervention for head and neck cancer survivors

Other: Survey Administration
Survey measures administered at BL, two and 6 months post-baseline

Active Comparator: Springboard Beyond Cancer

Springboard Beyond Cancer is a general resource for survivors of all cancer. It is a free self-management program for cancer survivors developed by trusted sources, the ACS and the NCI.

Other: Springboard Beyond Cancer
Informational online intervention for all cancer survivors

Other: Survey Administration
Survey measures administered at BL, two and 6 months post-baseline

Outcome Measures

Primary Outcome Measures

  1. Self-efficacy score [Baseline, two and 6 months post-baseline]

    Change in self- efficacy measured with the Self-efficacy scale (22 items) which targets confidence in managing aspects of self-care (e.g., dry mouth, swallowing, oral self-exam, communicating with providers, emotions). Administered at multiple time points to measure effect of the intervention. Ratings range from 1 (not at all confident) to 5 (very confident). An item average will be calculated.

  2. Preparedness for survivorship [Baseline, two and 6 months post-baseline]

    Change in preparedness for survivorship. The Preparedness for survivorship scale (10 items) developed by the investigator assesses whether information received about survivorship was sufficient, helpful, comprehensive, and covered self-care tasks. Administered at multiple time points to measure effect of the intervention. Items are rated on a 4-point Likert scale (1 = strongly disagree, 4 = strongly agree). Higher score indicate better preparedness.

  3. Quality of Life score measured using the The European Organization for Research and Treatment of Cancer (EORTC)- Head and Neck [Baseline, two and 6 months post-baseline]

    Change in QOL score over time. The European Organization for Research and Treatment of Cancer - Quality of Life Questionnaire- Head and Neck-43. The European Organization for Research and Treatment of Cancer - Quality of Life Questionnaire- Head and Neck-43 is the updated version of the EORTC H&N 35, used in the researcher's pilot work. The EORTC QLQ-HN is the most widely-used measure of Head and Neck QOL. The investigators use the total score in analyses, but will evaluate subscales. Administered at multiple time points to measure effect of the intervention. Items are rated on 1 (not at all)-4 (very much) Likert scale and higher scores indicate worse QOL.

Secondary Outcome Measures

  1. Performance of oral self-exam, past month [Baseline, two and 6 months post-baseline]

    1 item asking the participant if he/she has performed an oral self-exam, past month. Yes/No. Administered at multiple time points to measure effect of the intervention.

  2. Comprehensiveness is the number of areas checked (11 areas) during the oral self-exam [Baseline, two and 6 months post-baseline]

    Change in comprehensiveness of exams over time. 11 items will list the areas to check and ask participant to indicate Yes/No if the participant checked that area during the oral self-exam. Administered at multiple time points to measure effect of the intervention.

  3. Performance of exercises to improve swallowing, past month (yes/no) [Baseline, two and 6 months post-baseline]

    One question asking participants if they have completed exercises to improve swallowing in the past month. Administered at multiple time points to measure effect of the intervention.

  4. Performance of head/neck exercises, past month (yes/no) [Baseline, two and 6 months post-baseline]

    One question asking participants if they have completed head and neck exercises in the past month. Administered at multiple time points to measure effect of the intervention.

Other Outcome Measures

  1. Action and Planning Coping [Baseline, two and 6 months post-baseline]

    Change in Action and Planning coping score. The scale (8 items) assesses the degree to which a detailed plan is made for self-care tasks. Administered at multiple time points to measure effect of the intervention. Items are rated on a 5-point Likert scale(1 = strongly disagree, 5 = strongly agree). Mean scale score will be reported. Higher score = higher action coping.

  2. Patient activation [Baseline, two and 6 months post-baseline]

    Change in Patient activation scale score. Patient Activation Scale (13 items) assesses the active role in cancer care. Administered at multiple time points to measure effect of the intervention. Items are rated on a 4-point scale (1 = Disagree strongly, 4 = Agree strongly). Higher score = higher activation.

  3. Information Needs [Baseline, two and 6 months post-baseline]

    Change in score over time. Information needs (23 items) is adapted from the FOCUS Health-Related Topics measure. Administered at multiple time points to measure effect of the intervention. Participants reported if they would like more information on each topic (yes/no). The number of " yes" responses are averaged.

  4. Support needs [Baseline, two and 6 months post-baseline]

    Change in Support needs. The support needs scale (34 items) assesses physical, psychological, and health care needs. Administered at multiple time points to measure effect of the intervention. Participants are asked to indicate the extent to which they needed help in the past month (1 = No Need; Not applicable, "This is not a problem",2 = No need; Satisfied, "I did need help but my need was satisfied," 3 = Low need; "It caused me concern and I had little need for additional help," 4 = Moderate need-"It caused me concern and I had some need for additional help," 5 = High need; -"It caused me concern and I had a strong need for additional help"). Support needs that are rated as "moderate"(4) or "high" need (5) will be summed, with a range of 0 to 34.

  5. Concerns about recurrence scale [Baseline, two and 6 months post-baseline]

    Change in concerns about recurrence. The first 4 items from the concerns about recurrence scale are measured on a 1-6 scale. with lower scores indicating less concerns or worry. The additional 21 items are rated on 0 (not at all) to 4 (extremely) with higher scores indicating more concerns or worry. Administered at multiple time points to measure effect of the intervention.

  6. Moderator-Race/ethnicity [Baseline only]

    Race/ethnicity will be assessed.

  7. Moderator-Receipt of survivorship care plan [Baseline only]

    Yes/No did the participant receive a survivorship care plan

  8. Moderator- Baseline self-efficacy score [Baseline Only]

    The baseline score on the scale will be (22 items) examined. The scale targets confidence in managing aspects of self-care (e.g., dry mouth, swallowing, oral self-exam, communicating with providers, emotions). Ratings are 1- 5

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 89 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • age > 18 years;

  • Diagnosed with a first primary invasive oral or oropharyngeal cancer between 1 and 3 years ago;

  • Currently cancer free (but can have experienced a recurrence);

  • Has internet access;

  • Read English;

  • Has sufficient vision to read a survey and complete an online intervention

Exclusion Criteria:

Contacts and Locations

Locations

Site City State Country Postal Code
1 Rutgers Cancer Institute of New Jersey New Brunswick New Jersey United States 08901

Sponsors and Collaborators

  • Rutgers, The State University of New Jersey
  • National Cancer Institute (NCI)
  • The Cancer Registry of Greater California
  • The New Jersey State Cancer Registry

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Sharon Manne, PhD, Chief, Behavioral Sciences, Rutgers, The State University of New Jersey
ClinicalTrials.gov Identifier:
NCT04713449
Other Study ID Numbers:
  • Pro2020000768
  • 132004
First Posted:
Jan 19, 2021
Last Update Posted:
Jul 29, 2022
Last Verified:
Jul 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 29, 2022